| Website | metacure.com |
| Category | BioTech |
| Employees | |
| Description | Research for Diabetes Treatment |
| TOTAL | $20M |
| FUNDING TOTAL | $20M |
| Series B, 5/09 Morningside Group | $20M |
MetaCure develops implantable devices for the treatment of Type II (adult) diabetes. Their key product, Tantalus, delivers electrical pulses to the stomach when a person eats, causing gastric contractions.
